Patents by Inventor Michele L. R. Heffernan
Michele L. R. Heffernan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9708331Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: GrantFiled: February 2, 2016Date of Patent: July 18, 2017Assignee: Sunovion Pharmaceuticals Inc.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Publication number: 20160251359Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: ApplicationFiled: February 2, 2016Publication date: September 1, 2016Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe WU, Lakshmi D. Saraswat, Kerry L. Spear
-
Patent number: 9260452Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: GrantFiled: June 8, 2012Date of Patent: February 16, 2016Assignee: Sunovion Pharmaceuticals Inc.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Publication number: 20140349992Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: ApplicationFiled: June 9, 2014Publication date: November 27, 2014Applicant: Sunovion Pharmaceuticals Inc.Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Publication number: 20140221332Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: ApplicationFiled: May 25, 2012Publication date: August 7, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat
-
Patent number: 8772301Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: GrantFiled: December 17, 2010Date of Patent: July 8, 2014Assignee: Sunovion Pharmaceuticals, Inc.Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
-
Publication number: 20140179682Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: ApplicationFiled: June 8, 2012Publication date: June 26, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Publication number: 20110319380Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: ApplicationFiled: December 17, 2010Publication date: December 29, 2011Applicant: Sunovion Pharmaceuticals Inc.Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
-
Patent number: 7902252Abstract: The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.Type: GrantFiled: July 20, 2009Date of Patent: March 8, 2011Assignee: Sepracor, Inc.Inventors: Michele L. R. Heffernan, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Publication number: 20110034434Abstract: The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.Type: ApplicationFiled: August 6, 2010Publication date: February 10, 2011Applicant: SEPRACOR INC.Inventors: Michele L. R. Heffernan, Richard Dennis, James M. Dorsey, Robert J. Foglesong, Michael L. Jones, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear, Michael A. Orsini
-
Patent number: 7884124Abstract: This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.Type: GrantFiled: July 2, 2007Date of Patent: February 8, 2011Assignee: Sepracor Inc.Inventors: Michele L. R. Heffernan, Robert J. Foglesong, Seth C. Hopkins, Mustapha Soukri, Steven W. Jones, Kerry L. Spear, Mark A. Varney
-
Publication number: 20100120740Abstract: The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.Type: ApplicationFiled: August 6, 2009Publication date: May 13, 2010Applicant: SEPRACOR INC.Inventors: Michele L. R. Heffernan, Richard Dennis, James M. Dorsey, Robert J. Foglesong, Michael L. Jones, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear, H. Scott Wilkinson, Michael Anthony Orsini
-
Patent number: 7692019Abstract: One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of compounds useful for treatment of numerous ailments, conditions and diseases that afflict mammals, including but not limited to addiction and pain. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the substituted piperidines using the methods of the present invention. An additional aspect of the present invention relates to enantiomerically substituted pyrrolidines, piperidines, and azepines.Type: GrantFiled: February 28, 2006Date of Patent: April 6, 2010Assignee: Sepracor Inc.Inventors: Brian M. Aquila, Thomas D. Bannister, Gregory D. Cuny, James R. Hauske, Michele L. R. Heffernan, Michael Z. Hoemann, Donald W. Kessler, Liming Shao, Xinhe Wu, Roger L. Xie
-
Publication number: 20100029737Abstract: The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.Type: ApplicationFiled: July 20, 2009Publication date: February 4, 2010Applicant: SEPRACOR INC.Inventors: Michele L. R. Heffernan, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Publication number: 20100029741Abstract: This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: in which R1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R3 is a member selected from the group consisting of H, C1-C6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R4 is a member selected from OH and O?X+, in which X+ is positive ion which is a member selected from organic positive ions and inorganic positive ions.Type: ApplicationFiled: August 7, 2009Publication date: February 4, 2010Applicant: Sepracor Inc.Inventors: James M. Dorsey, Michele L. R. Heffernan, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Publication number: 20100022612Abstract: This invention provides fused heterocycles having the formula: in which R1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R3 is a member selected from the group consisting of H, C1-C6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R4 is a member selected from OH and O?X+, in which X+ is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.Type: ApplicationFiled: August 7, 2009Publication date: January 28, 2010Applicant: Sepracor Inc.Inventors: James M. Dorsey, Michele L. R. Heffernan, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Patent number: 7579370Abstract: This invention provides fused heterocycles having the formula: in which R1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R3is a member selected from the group consisting of H, C1-C6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R4 is a member selected from OH and O?X+, in which X+ is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.Type: GrantFiled: August 3, 2007Date of Patent: August 25, 2009Assignee: Sepracor Inc.Inventors: Michele L. R. Heffernan, James M. Dorsey, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Publication number: 20090099248Abstract: The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.Type: ApplicationFiled: January 18, 2008Publication date: April 16, 2009Applicant: SEPRACOR INC.Inventors: Michele L. R. Heffernan, Qun Kevin Fang, Robert J. Foglesong, Seth C. Hopkins, Cyprian O. Ogbu, Mustapha Soukri, Kerry L. Spear
-
Patent number: 7129228Abstract: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.Type: GrantFiled: January 7, 2004Date of Patent: October 31, 2006Assignee: Sepracor Inc.Inventors: Gregory D. Cuny, Liming Shao, James R. Hauske, Michele L. R. Heffernan, Brian M. Aquila, Xinhe Wu, Fengjiang Wang, Thomas D. Bannister
-
Patent number: 7087623Abstract: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors.Type: GrantFiled: February 25, 2004Date of Patent: August 8, 2006Assignee: Sepracor Inc.Inventors: Gregory D. Cuny, James R. Hauske, Michele L. R. Heffernan, Joanne M. Holland, Paul E. Persons, Heike Radeke